Urinary RetentionMANAGEMENT

GENITOURINARY AND REPRODUCTIVE PRESENTATIONS · 12 SECTIONS

⚲

554 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Acute Kidney Injury (ATN)Acute Kidney Injury (Post-renal)Acute Kidney Injury (Pre-renal)Amniotic Fluid Embolism Balanitis Bladder Rupture Breast Abscess Cystitis Dialysis access complications Ectopic pregnancy Epididymitis Glomerulonephritis Hematuria (gross)Hydrocele Interstitial Cystitis Mastitis Mittelschmerz Nephrolithiasis Nephrotic Syndrome Flare Nutcracker Syndrome Orchitis Ovarian Cyst Rupture Ovarian hyperstimulation syndrome Ovarian torsion Paraphimosis Pelvic Congestion Syndrome Pelvic Inflammatory Disease (PID)Peritoneal dialysis peritonitis Phimosis Priapism Prostatitis Pyelonephritis Renal laceration Renal transplant complications and rejection Ruptured ovarian cyst Testicular torsion Torsion of Appendix Testis Tubo-ovarian abscess Ureteral Rupture Urethritis Urinary Retention Urinary tract infection (uncomplicated)Urolithiasis (renal colic)Vaginal bleeding (non-pregnant)Vaginitis (Bacterial)Vaginitis (Candidal)Varicocele Vulvovaginal Hematoma

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp33

Immediate priorities

›Cannot-miss conditions requiring emergent action

›Cauda equina syndrome

›New bilateral leg weakness or numbness

›Saddle anesthesia (S2-S4 dermatomes)

›Bowel and bladder dysfunction together

›Emergent MRI lumbar spine without delay

›Spinal cord compression

›Symmetric limb weakness with sensory level

›Emergent neurosurgical consultation

›Urosepsis

›Fever, tachycardia, or hypotension with urinary retention

›Broad spectrum antibiotics within 1 hour of recognition

›Blood cultures before antibiotics

›Acute kidney injury from high-pressure chronic retention

›Creatinine elevation with bilateral hydronephrosis

›Urgent decompression and nephrology involvement

Hemodynamic monitoring

›Monitoring targets

›Blood pressure

›SBP < 90 mmHg triggers resuscitation

›Autonomic dysreflexia in spinal cord injury patients: SBP spike above 200 mmHg

›Heart rate

›Tachycardia may indicate pain, infection, or decompensation

›Temperature

›Fever > 38.3 C with retention indicates infectious etiology

Stabilization actions

›Immediate decompression

02History/hx76

Voiding symptoms

›Lower urinary tract symptom profile

›Obstructive symptoms

›Hesitancy

›Weak or intermittent stream

›Straining to void

›Sensation of incomplete emptying

›Post-void dribbling

›Storage symptoms

›Urinary frequency

›Urgency

›Nocturia

›Overflow incontinence

Onset and context

›Temporal characterization

›Acute onset (sudden, painful, complete inability to void)

›Duration since last void

›Precipitating event: surgery, anesthesia, new medication

›Chronic or subacute onset (gradual, often painless, elevated PVR)

›Progressive worsening over weeks to months

›May present without suprapubic pain despite large volumes

›Pain characterization

›Suprapubic fullness or pressure

›Perineal pain suggesting prostatitis

›Back or leg pain suggesting neurologic etiology

Medication history

›High-risk medications for urinary retention

›Anticholinergic agents

03Physical Exam/exam53

Vital signs

›Hemodynamic and infectious assessment

›Blood pressure

›Hypertension from pain or autonomic dysreflexia in SCI

›Hypotension suggesting septic shock

›Temperature

›Fever with retention suggests prostatitis, UTI, or urosepsis

›Heart rate

›Tachycardia as sepsis or pain marker

›Respiratory rate

›Elevation in decompensating sepsis

Abdominal exam

›Bladder and abdominal assessment

›Suprapubic inspection

›Visible lower abdominal distension

›Midline suprapubic fullness

›Palpation

›Tender palpable bladder mass above pubic symphysis

›Pain with percussion over distended bladder

›Absence of suprapubic tenderness does not exclude chronic retention

Genital and pelvic exam

›Targeted genital examination

›Male exam

›Phimosis or meatal stenosis as obstructive cause

›Urethral discharge suggesting STI-related stricture

›Scrotal or penile pathology

›Female exam

›Pelvic organ prolapse as obstructive cause in women

04Differential Diagnosis/ddx45

Obstructive causes

›Anatomic obstruction

›Benign prostatic hyperplasia (ICD-10: N40.1)

›Most common cause in men, accounting for approximately 53% of AUR cases

›Distinguishing feature: LUTS history, enlarged prostate on DRE

›Urethral stricture (ICD-10: N35.9)

›History of urethral instrumentation, STI, or perineal trauma

›Difficult or impossible catheter passage

›Pelvic organ prolapse (ICD-10: N81.9)

›Most common obstructive cause in women

›Visible prolapse on pelvic exam

›Bladder neck obstruction (ICD-10: N32.0)

›Post-TURP or post-radiation scarring

›Prostate or bladder malignancy (ICD-10: C61, C67)

›Weight loss, hematuria, nodular prostate

Infectious and inflammatory causes

›Infectious etiologies

›Acute bacterial prostatitis (ICD-10: N41.0)

›Fever, perineal pain, tender boggy prostate on DRE

›21% of acute bacterial prostatitis cases have bacteremia

›Avoid vigorous DRE to minimize bacteremia risk

›Urinary tract infection or cystitis (ICD-10: N30.0)

›Dysuria, frequency, suprapubic pain

›Edema of bladder neck causing functional obstruction

›Urethritis (ICD-10: N34.1)

›Urethral discharge, STI risk factors

Neurogenic causes

›Neurologic etiologies

05Laboratory Tests/lt34

Urinalysis and urine culture

›Urine studies

›Urinalysis

›Pyuria and bacteriuria: UTI or prostatitis

›Hematuria: malignancy, stones, or infection

›Glucosuria: uncontrolled diabetes with autonomic neuropathy

›Urine culture

›Indicated when UA suggests infection

›Guide antibiotic selection if catheterization performed with signs of infection

Renal function

›Metabolic and renal assessment

›Serum creatinine and electrolytes

›Elevated creatinine indicates obstructive nephropathy

›Chronic high-pressure retention may present with silent renal failure

›Electrolyte abnormalities pre-alert to post-obstructive diuresis risk

›BUN

›Elevation suggests renal compromise or dehydration

Infection markers

›Systemic infection assessment

›Complete blood count

›Leukocytosis with left shift: prostatitis, urosepsis

›Leukopenia in severe sepsis

›Blood cultures

›Obtained before antibiotics when urosepsis suspected

›21% of acute bacterial prostatitis patients have bacteremia

›Lactate

›Level >= 2 mmol/l suggests tissue hypoperfusion

›Level >= 4 mmol/l indicates septic shock even without hypotension

06Diagnostic Tests/dt49

Scoring Systems

›International Prostate Symptom Score (IPSS)

›Seven-item validated questionnaire for LUTS severity

›Score 0-7: mild symptoms

›Score 8-19: moderate symptoms

›Score 20-35: severe symptoms

›Used in outpatient BPH monitoring and TWOC planning

›Correlates with treatment response to alpha-blockers

›Post-void residual (PVR) classification

›PVR thresholds

›PVR < 50 mL: normal

›PVR 50-300 mL: elevated; clinical context determines management

›PVR > 300 mL: significant retention; catheterization typically indicated

›PVR > 1000 mL: high-pressure chronic retention; renal function assessment mandatory

MRI

›MRI indications in urinary retention

›MRI lumbar spine

›First-line imaging for suspected cauda equina syndrome

›Emergent; do not delay for lab results when CES is suspected

›Sensitivity > 90% for disc herniation and epidural compression

›MRI pelvis

›Pelvic malignancy evaluation when CT inconclusive

›Prostate cancer local staging

›Pelvic floor dysfunction and anatomy

›MRI brain and spine

›Demyelinating disease (MS) evaluation when neurogenic bladder suspected

›Spinal cord signal abnormality in compressive myelopathy

07Disposition/dispo38

Admission criteria

›Indications for hospital admission

›Infectious and septic indications

›Urosepsis or hemodynamic instability

›Acute bacterial prostatitis requiring IV antibiotics

›Failed outpatient antibiotic course

›Renal and metabolic indications

›Acute kidney injury or significant creatinine elevation

›Significant electrolyte abnormalities

›Post-obstructive diuresis requiring IV fluid management

›Neurologic emergencies

›Suspected cauda equina syndrome: emergent admission and surgical evaluation

›Acute spinal cord compression: neurosurgery and oncology involvement

›Failed catheterization

›Urology consultation for suprapubic catheter placement

›High-risk patients

›Delirium or altered mental status precipitating retention

›Elderly with significant comorbidities and hemodynamic instability

›Fecal impaction requiring inpatient disimpaction

Discharge criteria

›Safe discharge requirements

›Successful catheterization with adequate drainage

›Foley bag management instructions provided

›Home health support arranged if needed

›Stable vital signs without signs of infection or renal compromise

›Alpha-blocker initiated at time of catheter placement

›TWOC planned within 48-72 hours

›Urology or primary care follow-up arranged

08Treatment/t77

Immediate decompression

›Bladder catheterization protocol

›Urethral catheterization

›Foley catheter 14-18 Fr for standard cases

›Coude tip catheter for suspected prostatic enlargement or angulation

›Lubricate generously; do not force against resistance

›Suprapubic catheter if urethral approach fails

›Urology-performed under ultrasound guidance

›Indications: urethral trauma, stricture, artificial sphincter

›Intermittent catheterization

›Preferred over indwelling catheter for lower volume retention in appropriate patients

›Reduces catheter-associated UTI risk

›Post-decompression monitoring

›Record initial drained volume

›Monitor urine output for post-obstructive diuresis if PVR > 1000 mL

›Replace urine output > 200 mL/hr with 0.45% NaCl to prevent severe diuresis

Alpha-blocker therapy

›Pharmacologic therapy for TWOC success

›Tamsulosin

›Dose: 0.4 mg orally once daily

›Start at time of catheter insertion

›Selective alpha-1A blocker; preferred first-line agent

›Alfuzosin

›Dose: 10 mg orally once daily with food

›Extended-release formulation

›Evidence base

›Alpha-blocker therapy improves TWOC success rate: 60% vs 38% with placebo

›Cochrane systematic review supports alpha-blocker pre-TWOC (Class I evidence)

›Prolonged catheterization beyond 3 days does not further improve TWOC success

Trial without catheter

›TWOC protocol

›Timing

›Remove catheter after 48-72 hours of alpha-blocker therapy

›Prolonged catheterization > 3 days increases complication risk without benefit

›Setting

›TWOC can be performed in outpatient or ED setting

›Patient must attempt voiding within 4-6 hours of catheter removal

›Success criteria

›Spontaneous void with comfortable PVR < 300 mL

›Failure criteria

›Unable to void within 4-6 hours after removal

›Symptomatic discomfort with PVR > 300 mL

›Failed TWOC: recatheterize and arrange urology follow-up

Management of offending medications

›Drug-induced retention management

›Discontinue causative agent when possible

›Anticholinergics, opioids, sympathomimetics

›Substitute with lower anticholinergic burden alternative

›Beers Criteria guidance in elderly

›Avoid anticholinergics in older adults with bladder outlet obstruction

›High-risk agents include first-generation antihistamines, TCAs, antipsychotics

Infection treatment

›Antimicrobial therapy for infectious etiologies

›Acute bacterial prostatitis

›Fluoroquinolone preferred: ciprofloxacin 500 mg orally twice daily for 4-6 weeks

›If systemic infection: IV ciprofloxacin 400 mg IV every 12 hours until clinically improved then oral step-down

›Alternative for penicillin allergy or fluoroquinolone resistance: trimethoprim-sulfamethoxazole DS twice daily for 4-6 weeks

›UTI-related retention

›Nitrofurantoin 100 mg modified-release twice daily for 5 days for uncomplicated

›Broader coverage for complicated UTI: cephalexin 500 mg four times daily or ciprofloxacin 250 mg twice daily for 7 days

›Urosepsis

›Piperacillin-tazobactam 4.5 g IV every 6 hours

›Alternative: ceftriaxone 2 g IV daily if low-risk for resistant organisms

›Meropenem 1 g IV every 8 hours if ESBL or MDR organism suspected

Long-term BPH management

›Outpatient BPH treatment

›5-alpha reductase inhibitors

›Finasteride 5 mg orally once daily

›Dutasteride 0.5 mg orally once daily

›Onset of effect: 3-6 months

›Combination therapy (alpha-blocker + 5ARI) for larger prostates > 40 mL

›Surgical options for refractory BPH

›Transurethral resection of the prostate (TURP): gold standard

›Holmium laser enucleation of the prostate (HoLEP): effective for large prostates

›Minimally invasive procedures: prostatic urethral lift (UroLift), steam ablation

Neurogenic bladder management

›Neurogenic bladder treatment

›Clean intermittent self-catheterization (CIC)

›Mainstay of treatment for neurogenic bladder

›AUA/SUFU guideline: CIC preferred over indwelling catheter

›Frequency: every 4-6 hours to maintain bladder volume < 400 mL

›Specialist referral

›Urology or urogynecology for urodynamic evaluation

›Neurology for underlying neurologic disease management

09Special Populations/sp52

Pregnancy

›Urinary retention in pregnancy

›Etiology

›Retroverted gravid uterus (most common in first trimester)

›Pelvic mass or fibroid compressing bladder outlet

›Epidural or spinal analgesia during labor

›Clinical features

›Often presents at 12-16 weeks gestation with incarcerated uterus

›Suprapubic pain and inability to void

›Management

›Urethral catheterization for immediate decompression

›Manual uterine repositioning by obstetrics

›Catheter maintained until uterus spontaneously rises above pelvic brim

›Medication safety

›Alpha-blockers are contraindicated in pregnancy (teratogenic in animal studies)

›Avoid fluoroquinolones (cartilage risk); use cephalexin or nitrofurantoin for UTI

›Nitrofurantoin avoided near term (> 36 weeks): neonatal hemolytic anemia risk

Geriatric

›Urinary retention in older adults

›Epidemiology

›Mean age of ED presentation is 72 years

›Highest incidence in 75-85 year age group

›Mortality within one year after AUR episode is higher than general population

›Precipitating factors

›Delirium is a common precipitant and may mask retention symptoms

›Constipation and fecal impaction as independent precipitants

›High anticholinergic medication burden (Beers Criteria)

›Modified assessment

10Background/b44

Epidemiology

›Incidence and prevalence

›Acute urinary retention

›BPH accounts for approximately 53% of AUR cases in men

›Predominantly affects men; rare in women

›Annual incidence of AUR in men: approximately 3 per 1000 men aged 45-49 rising to 30 per 1000 in men aged 75-79

›Risk of AUR in men with BPH over 5 years: 3-5%

›ED demographics

›Mean age of ED presentation: 72 years

›African American and Hispanic men overrepresented in ED presentations for AUR

›Mortality and morbidity

›Mortality within one year following AUR is higher than in the general population

›High-pressure chronic retention can lead to silent irreversible renal failure

Pathophysiology

›Mechanisms of urinary retention

›Obstructive mechanism

›Anatomic obstruction increases bladder outlet resistance

›Bladder compensates with detrusor hypertrophy then decompensates with overdistension

›Chronic overdistension leads to detrusor failure and elevated PVR

›Pharmacologic mechanism

›Anticholinergics block muscarinic M2 and M3 receptors on detrusor

›Alpha-agonists increase smooth muscle tone at bladder neck and urethra

›Opioids suppress detrusor via kappa and mu receptor activation

›Neurogenic mechanism

›Upper motor neuron lesions cause detrusor overactivity with dyssynergia

›Lower motor neuron lesions cause atonic acontractile bladder

›Cauda equina injury disrupts sacral micturition center (S2-S4)

›Classification

11Patient Discharge Instructions/pdi29

copy discharge instructions

›Urinary Retention - Discharge Instructions

›What happened

›Your bladder was unable to empty and needed to be drained with a catheter (tube)

›You are going home with a catheter in place to drain your bladder until a follow-up appointment

›Catheter care at home

›Keep the catheter bag below the level of your bladder at all times

›Empty the drainage bag when it is two-thirds full

›Clean around the catheter entry site daily with soap and water

›Drink at least 6-8 glasses of water daily to prevent blockage or infection

›Do not kink or clamp the tubing

›Medications

›Take tamsulosin (or alfuzosin) as prescribed every day until your follow-up visit

›This medication relaxes the bladder outlet to help you void when the catheter is removed

›Do not take OTC cold or allergy medications containing pseudoephedrine or diphenhydramine

›Diet and lifestyle

›Limit caffeine and alcohol as they can worsen bladder symptoms

›Eat high-fiber foods or use a fiber supplement to prevent constipation

›Constipation can block normal bladder emptying

›Follow-up appointment

›Return to your doctor or urologist within 48-72 hours for a trial without catheter (catheter removal attempt)

›If the trial fails you may need the catheter replaced and will be referred to urology for further evaluation

›Return to Emergency Department immediately if

›You are unable to void after the catheter is removed

›Fever above 38.3 C or chills

›Worsening suprapubic pain or pressure

›Blood in your urine or around the catheter

›Catheter stops draining urine

12References/r24

Guidelines and key sources

›Primary clinical references

›Serlin DC, Heidelbaugh JJ, Stoffel JT. Urinary Retention in Adults: Evaluation and Initial Management. American Family Physician. 2018. PMID 30277739

›Comprehensive primary care and ED management guideline

›Wei JT, Dauw CA, Brodsky CN. Lower Urinary Tract Symptoms in Men. JAMA. 2025.

›Updated evidence review on BPH and LUTS management

›Fisher E, Subramonian K, Omar MI. The Role of Alpha Blockers Prior to Removal of Urethral Catheter for Acute Urinary Retention in Men. Cochrane Database of Systematic Reviews. 2014.

›Cochrane meta-analysis: alpha-blockers improve TWOC success (60% vs 38%)

›Karavitakis M, Kyriazis I, Omar MI, et al. Management of Urinary Retention in Patients With Benign Prostatic Obstruction: A Systematic Review and Meta-Analysis. European Urology. 2019. PMID 30773327

›Supports alpha-blocker initiation at catheter placement

Neurologic and emergency references

›Neurologic and emergency medicine sources

›Kuris EO, McDonald CL, Palumbo MA, Daniels AH. Evaluation and Management of Cauda Equina Syndrome. The American Journal of Medicine. 2021. PMID 34473966

›Emergent MRI and surgical consultation pathway

›Long B, Koyfman A, Gottlieb M. Evaluation and Management of Cauda Equina Syndrome in the Emergency Department. The American Journal of Emergency Medicine. 2020. PMID 31471075

›EM-focused cauda equina review

›Ropper AE, Ropper AH. Acute Spinal Cord Compression. NEJM. 2017.

›Comprehensive review of cord compression management

›Ginsberg DA, Boone TB, Cameron AP, et al. The AUA/SUFU Guideline on Adult Neurogenic Lower Urinary Tract Dysfunction. J Urology. 2021.

›Urodynamics and CIC recommendations for neurogenic bladder

›Thorne MB, Geraci SA. Acute Urinary Retention in Elderly Men. The American Journal of Medicine. 2009. PMID 19699373

›Geriatric-specific epidemiology and management considerations

›Verhamme KM, Sturkenboom MC, Stricker BH, Bosch R. Drug-Induced Urinary Retention. Drug Safety. 2008. PMID 18422378

›Drug class review for medication-induced retention

›Chrouser K, Fowler KE, Mann JD, et al. Urinary Retention Evaluation and Catheterization Algorithm for Adult Inpatients. JAMA Network Open. 2024.

›Structured catheterization protocol reducing inappropriate catheter use

Learn More: Urinary Retention→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.